Sarmad Sadeghi talks about their phase 2 trial pointing to the potential of combining the novel EphrinB2 pathway inhibitor sEphB4-HSA with pembrolizumab in previously treated patients with metastatic urothelial carcinoma (3:51).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany